Erratum for

• Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.

  Voorberg AN, Kamphuis E, Christoffers WA, Schuttelaar MLA. Voorberg AN, et al. Br J Dermatol. 2023 Sep 15;189(4):400-409. doi: 10.1093/bjd/ljad156. Br J Dermatol. 2023. PMID: 37170922 Clinical Trial.
• Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in patients with leukaemic cutaneous T-cell lymphoma.

  Tsai YC, Schlaepfer T, Ignatova D, Chang YT, Valaperti A, Amarov B, Blanchard G, Pehr K, Vonow-Eisenring M, Urosevic-Maiwald M, Hoetzenecker W, Pascolo S, Iselin C, Fassnacht C, Dimitriou F, Bobrowicz M, Guenova E. Tsai YC, et al. Br J Dermatol. 2023 Oct 25;189(5):603-611. doi: 10.1093/bjd/ljad220. Br J Dermatol. 2023. PMID: 37409661
• Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).

  Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA. Stein Gold LF, et al. Br J Dermatol. 2023 Oct 25;189(5):540-552. doi: 10.1093/bjd/ljad252. Br J Dermatol. 2023. PMID: 37488811 Clinical Trial.
• Metformin has anti-inflammatory effects and induces immunometabolic reprogramming via multiple mechanisms in hidradenitis suppurativa.

  Petrasca A, Hambly R, Kearney N, Smith CM, Pender EK, Mac Mahon J, O'Rourke AM, Ismaiel M, Boland PA, Almeida JP, Kennedy C, Zaborowski A, Murphy S, Winter D, Kirby B, Fletcher JM. Petrasca A, et al. Br J Dermatol. 2023 Nov 16;189(6):730-740. doi: 10.1093/bjd/ljad305. Br J Dermatol. 2023. PMID: 37648653
• Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.

  Flohr C, Rosala-Hallas A, Jones AP, Beattie P, Baron S, Browne F, Brown SJ, Gach JE, Greenblatt D, Hearn R, Hilger E, Esdaile B, Cork MJ, Howard E, Lovgren ML, August S, Ashoor F, Williamson PR, McPherson T, O'Kane D, Ravenscroft J, Shaw L, Sinha MD, Spowart C, Taams LS, Thomas BR, Wan M, Sach TH, Irvine AD; TREAT Trial Investigators. Flohr C, et al. Br J Dermatol. 2023 Nov 16;189(6):674-684. doi: 10.1093/bjd/ljad281. Br J Dermatol. 2023. PMID: 37722926 Clinical Trial.
• Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.

  Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguier MA, Ingen-Housz-Oro S, Pham-Ledard A, Bedane CR, Picard-Dahan C, Berthin C, Dereure O, Konstantinou MP, Castel M, Jouen F, Joly P, Seta V, Duvert-Lehembre S, Le Roux C, Quereux G, Sassolas B, Brenaut E, Sin C, Richard MA, Bérard F, Giusti D, Belmondo T, Gille T, Caux F, Prost-Squarcioni C, Grootenboer-Mignot S, Alexandre M; French Study Group on Autoimmune Bullous Diseases. Chebani R, et al. Br J Dermatol. 2024 Jan 23;190(2):258-265. doi: 10.1093/bjd/ljad369. Br J Dermatol. 2024. PMID: 37792727
• A critical role of the endothelial S-phase kinase-associated protein 2/phosphatase and tensin homologue axis in angiogenesis and psoriasis.

  Xie X, Cui Q, Jiang T, Zhao Z, Liu Z, Liu J, Yao Q, Wang Y, Dang E, Wang G, Xiao L, Wang N. Xie X, et al. Br J Dermatol. 2024 Jan 23;190(2):244-257. doi: 10.1093/bjd/ljad399. Br J Dermatol. 2024. PMID: 37850885
• Long noncoding RNA plasmacytoma variant translocation 1 is overexpressed in cutaneous squamous cell carcinoma and exon 2 is critical for its oncogenicity.

  Li C, Sun C, Mahapatra KD, Riihilä P, Knuutila J, Nissinen L, Lapins J, Kähäri VM, Homey B, Sonkoly E, Pivarcsi A. Li C, et al. Br J Dermatol. 2024 Feb 16;190(3):415-426. doi: 10.1093/bjd/ljad419. Br J Dermatol. 2024. PMID: 37930852
• Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease.

  Strobl J, Gail LM, Krecu L, Madad S, Kleissl L, Unterluggauer L, Redl A, Brazdilova K, Saluzzo S, Wohlfarth P, Knaus HA, Mitterbauer M, Rabitsch W, Haniffa M, Stary G. Strobl J, et al. Br J Dermatol. 2024 Feb 16;190(3):402-414. doi: 10.1093/bjd/ljad402. Br J Dermatol. 2024. PMID: 38010706 Free PMC article.
• Breastfeeding decreases the risk of developing psoriasis through to early adulthood.

  Das D, Thimjo J, Lebena A, Guo A, Enerbäck C, Ludvigsson J. Das D, et al. Br J Dermatol. 2024 Jun 20;191(1):65-74. doi: 10.1093/bjd/ljae043. Br J Dermatol. 2024. PMID: 38305572
• Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.

  Grekowitz E, Metz M, Altrichter S, Bauer A, Brockow K, Heine G, Lionnet L, Saday KK, Hultsch T, Søerensen OE, Maurer M. Grekowitz E, et al. Br J Dermatol. 2024 May 17;190(6):825-835. doi: 10.1093/bjd/ljae038. Br J Dermatol. 2024. PMID: 38308655 Clinical Trial.